Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATNON: Concurrent and Adjuvant Temozolomide in Non‑1p/19q Deleted Anaplastic Glioma
2006-001533-17Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in anaplastic glioma and glioblastoma (GBM) (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Apr 2007; status: completed.
02
Drugs
temozolomide
03
Conditions
anaplastic gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on 2006-001533-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001533-17.